25/04/2022

Opinion: A long journey to care, or why it’s time for an ambitious EU framework for a cross-border healthcare

22/11/2021

The review of the general pharmaceutical legislation: an opportunity that should not be missed?

26/07/2021

EuropaBio response to the European Commission Public Consultation on the Regulation for Orphan Medicinal Products and Paediatrics: the value brought by the technology to patients and society should be well recognised

31/05/2021

EuropaBio Key Messages to 94th Pharmaceutical Committee – 28 May 2021

20/05/2021

Decentralised clinical trials, the future of clinical research

The COVID-19 pandemic has been a catalyst for change which has led us to revisit the way we conduct clinical trials.
16/04/2021

EuropaBio Response to the Public Consultation on Blood, tissues and cells for medical treatments & therapies

EuropaBio welcomes the in-depth opinion of the European Group on Ethics on the uses of genome editing and thanks the Group for raising the awareness of a technology which will enable the development of many solutions for healthy people and planet.
12/02/2021

EuropaBio Response to Public Consultation on the Evaluation of Patient Rights in Cross-Border Healthcare

EuropaBio sees the Directive on cross-border healthcare as an important instrument to ensure patient access to the best available care. The Directive is particularly relevant for advanced therapies and medicines for rare diseases.
04/02/2021

EuropaBio draft response to the IIA on European Health Data Space

EuropaBio welcomes the European Commission’s plan to begin a discussion with stakeholders to develop the EHDS.
20/10/2020

EuropaBio on Use of Real-World Data (RWD) and Real-World Evidence (RWE) for regulatory decision-making

EuropaBio Position Paper on the use of Real-World Data (RWD) and Real-World Evidence (RWE) for regulatory decision-making.
19/10/2020

Application of the ATMP Hospital Exemption in the EU

EuropaBio and its members would like to engage the European Commission and all relevant stakeholders in a discussion on the future use of the HE in the context of the new EU Pharmaceutical Strategy and its accompanying actions.
28/06/2018

Joint Pharmaceutical Industry Statement on the Commission’s Proposal for a Regulation on Health Technology Assessment (HTA)

The Pharmaceutical Industry generally welcomes the European Commission’s Proposal for a Regulation on HTA.
06/06/2017

EuropaBio launches recommendations to enhance transparency of biosimilar labels

This document outlines the proposals put forth by EuropaBio members with regard to the changes to the Summary of Product Characteristics (SmPC) of biosimilars, which we consider would result in an enhanced level of transparency in the label.
27/05/2017

Biosimilar SmPC Recommendations

This document outlines the proposals put forth by EuropaBio members with regard to the changes to the Summary of Product Characteristics (SmPC) of biosimilars, which we consider would result in an enhanced level of transparency in the label.
23/01/2017

European Commission Initiative Improves Information for Patients on Biosimilar Medicines

European Commission Initiative Improves Information for Patients on Biosimilar Medicines.
Become a member